Wechat/Whatsapp:+ 86 19831061835

Cagrilintide is a novel compound that holds promise as a therapeutic agent with several potential health benefits. As a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue, it has garnered attention in the field of research for its multifaceted effects on metabolic processes and potential applications in improving health outcomes.
Not to be confused with CagriSema. A combo of Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It is injected once weekly in research test subjects and is being tested in type 2 diabetes and obesity.